KRAS and non-small cell lung carcinoma: These chemicals should be further explored to evaluate the therapeutic efficacy in KRAS mutated NSCLC under hypoxia conditions Although this study brings new insights to elucidate the effects of hypoxic response upon KDACi treatments on metabolic reprogramming, it is important to mention that the present study did not assess whether wild-type KRAS cells undergo distinct metabolic reprogramming events upon KDAC inhibition.